Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8274287 | 0.88 | RIPK1 (0.41) | SCN9ARIPK1NPY1RCYP1A2CYP2C19 | |
| SCHEMBL8274769 | 0.86 | SCN9A (0.43) | SCN9ARIPK1NPY1RCYP1A2CYP2C19 | |
| SCHEMBL8273830 | 0.84 | SCN9A (0.47) | SCN9ARIPK1NPY1R | |
| Hydrochloric Acid SCHEMBL4897081 | 0.82 | CYP1A2 (0.44) | RIPK1CYP1A2CYP2C19KMT2A | |
| SCHEMBL8273819 | 0.82 | RIPK1 (0.44) | SCN9ARIPK1 | |
| SCHEMBL6762780 | 0.80 | EPHX2 (0.43) | SCN9ARIPK1KMT2AL3MBTL1 | |
| SCHEMBL4897407 | 0.77 | CYP1A2 (0.39) | RIPK1CYP1A2CYP2C19KMT2ACNR1 | |
| SCHEMBL4886164 | 0.76 | MEN1 (0.39) | RIPK1CYP1A2CYP2C19CHRM1KMT2A | |
| SCHEMBL7416762 | 0.76 | NPY1R (0.59) | SCN9ANPY1RKMT2AL3MBTL1 | |
| SCHEMBL5132571 | 0.76 | NPY1R (0.59) | SCN9ANPY1RKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | SCN9A 718/4885RIPK1 3999/4885NPY1R 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.